FIREHAWK®

Healthcare Professionals Cardiovascular Percutaneous Coronary Intervention Firehawk

Firehawk® Rapamycin Target Eluting Coronary Stent System Features

Clinical Evidence

TARGET All Comers Trial¹

1,656 Patients from 20 sites in Europe
1:1 RCT Real World open-label, non-inferiority trial
Primary endpoint: TLF @12 months
Confirms that the Firehawk®, a low dose sirolimus eluting biodegradable polymer DES, is safe
and effective across a broad spectrum of patient and lesion complexity

Prob/Definite stent Thrombosis at 1 year

1-year Stent thrombosis rate result shows non-inferiority than Durable-Polymer DES
Shows proven safety in all comers population

Product Specification

Stent Material:	L605 CoCr
Polymer:	PLA, 100% Biodegradable
Drug:	Rapamycin (Sirolimus)
Drug Dosage:	0.3 µg/mm²
Strut Thickness:	86µm (Ø2.25mm - 3.0mm) 96.5µm (Ø3.5mm - 4.0mm)
Nomial Pressure:	10 atm
Rated Burst Pressure:	16 atm (Ø2.25mm - 3.5mm) 14 atm (Ø4.0mm)
Mean Recoil:	3.4%
Mean Foreshortening:	1.95% - 5.30%

Ordering Information

Length /Ø

8mm

13mm

16mm

18mm

21mm

23mm

26mm

29mm

31mm

33mm

35mm

38mm

2.25mm

RV2208

RV2213

RV2216

RV2218

RV2221

RV2223

RV2226

RV2229

2.5mm

RV2508

RV2513

RV2516

RV2518

RV2521

RV2523

RV2526

RV2529

RV2531

RV2533

2.75mm

RV2708

RV2713

RV2716

RV2718

RV2721

RV2723

RV2726

RV2729

RV2731

RV2733

RV2735

RV2738

3.0mm

RV3008

RV3013

RV3016

RV3018

RV3021

RV3023

RV3026

RV3029

RV3031

RV3033

RV3035

RV3038

3.5mm

RV3508

RV3513

RV3516

RV3518

RV3521

RV3523

RV3526

RV3529

RV3531

RV3533

RV3535

RV3538

4.0mm

RV4008

RV4013

RV4016

RV4018

RV4021

RV4023

RV4026

RV4029

RV4031

RV4033

RV4035

RV4038

1 Lansky, A., Wijns, W., Xu, B.,…Baumbach, A.(2018). Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable polymer coronary stent (TARGET All Comers): a multicentre, open-label, randomised non-inferiority trial. Lancet. Doi: 10.1016/S0140-6736(18)31649-0